Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Neurogenesis Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is being reviewed by 1 distinct examiner across 1 distinct art unit. This highly focused profile indicates that the company's current interactions with the patent office are limited to a single technical application. Because the prosecution is confined to 1 distinct art unit, the company can tailor its approach to the specific standards of that administrative group.
Emily Ann Cordas is the busiest examiner for this portfolio, holding 1 pending office action. This examiner is responsible for the company's entire pending workload at this time. With only 1 distinct examiner involved, the company's success in the Biotechnology & Pharmaceuticals field is currently subject to the specific requirements of this one individual. There are no other examiners or art units present in the data to offer a baseline for comparing allowance rates or prosecution timelines. This makes the relationship with the assigned examiner a critical factor for the company's current patent strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CORDAS, EMILY ANN | 1 | 50.9% | +57.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033629 | MESENCHYMAL STEM CELLS AND THEIR CULTURE | CORDAS, EMILY ANN | 33d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033629 | MESENCHYMAL STEM CELLS AND THEIR CULTURE | CORDAS, EMILY ANN | 33d |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18033629 | MESENCHYMAL STEM CELLS AND THEIR CULTURE | CORDAS, EMILY ANN | 1632 | §102§112 | Non-Final OA | 33d | Pending | Apr 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNeurogenesis Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Emily Ann Cordas has the most, with 1 of Neurogenesis Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
